## Marie E Wood

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5293119/publications.pdf

Version: 2024-02-01

33 papers 1,038 citations

687363 13 h-index 501196 28 g-index

34 all docs

34 docs citations

34 times ranked 1659 citing authors

#	Article	IF	CITATIONS
1	Second Malignant Neoplasms: Assessment and Strategies for Risk Reduction. Journal of Clinical Oncology, 2012, 30, 3734-3745.	1.6	263
2	American Society of Clinical Oncology Expert Statement: Collection and Use of a Cancer Family History for Oncology Providers. Journal of Clinical Oncology, 2014, 32, 833-840.	1.6	210
3	Quality of Cancer Family History and Referral for Genetic Counseling and Testing Among Oncology Practices: A Pilot Test of Quality Measures As Part of the American Society of Clinical Oncology Quality Oncology Practice Initiative. Journal of Clinical Oncology, 2014, 32, 824-829.	1.6	146
4	Disparities in uptake of BRCA1/2 genetic testing in a randomized trial of telephone counseling. Genetics in Medicine, $2015$ , $17$ , $467-475$ .	2.4	86
5	Interviews with primary care physicians regarding taking and interpreting the cancer family history. Family Practice, 2008, 25, 334-340.	1.9	70
6	Development of a predictive miRNA signature for breast cancer risk among high-risk women. Oncotarget, 2017, 8, 112170-112183.	1.8	30
7	Increasing Adherence to Adjuvant Hormone Therapy Among Patients With Breast Cancer: A Smart Phone App-Based Pilot Study. Cancer Control, 2019, 26, 107327481988328.	1.8	23
8	Risk for breast cancer and management of unaffected individuals with nonâ€BRCA hereditary breast cancer. Breast Journal, 2020, 26, 1528-1534.	1.0	20
9	Identifying key barriers to effective breast cancer control in rural settings. Preventive Medicine, 2021, 152, 106741.	3.4	20
10	Comparison of false positive rates for screening breast magnetic resonance imaging (MRI) in high risk women performed on stacked versus alternating schedules. SpringerPlus, 2015, 4, 77.	1.2	19
11	The Effect of Atorvastatin on Breast Cancer Biomarkers in High-Risk Women. Cancer Prevention Research, 2016, 9, 379-384.	1.5	19
12	Multi-gene panel testing for hereditary cancer susceptibility in a rural Familial Cancer Program. Familial Cancer, 2017, 16, 159-166.	1.9	16
13	Effect of neuromuscular electrical stimulation on skeletal muscle size and function in patients with breast cancer receiving chemotherapy. Journal of Applied Physiology, 2020, 128, 1654-1665.	2.5	15
14	Contribution of extended family history in assessment of risk for breast and colon cancer. BMC Family Practice, 2016, 17, 126.	2.9	13
15	Importance of family history and indications for genetic testing. Breast Journal, 2020, 26, 100-104.	1.0	13
16	Trousseau's syndrome treated with long-term subcutaneous lepirudin (case report and review of the) Tj ETQq0 (	0 0 rgBT /0	Overlock 10 Tf
17	Ductal Carcinoma In Situ: A Brief Review of Treatment Variation and Impacts on Patients and Society. Critical Reviews in Eukaryotic Gene Expression, 2014, 24, 281-286.	0.9	11
18	Multi-institutional Evaluation of Women at High Risk of Developing Breast Cancer. Clinical Breast Cancer, 2017, 17, 427-432.	2.4	11

#	Article	IF	CITATIONS
19	Towards a more precise and individualized assessment of breast cancer risk. Aging, 2019, 11, 1305-1316.	3.1	9
20	The Influence of Vitamin D on Mammographic Density: Results from CALGB 70806 (Alliance) a Randomized Clinical Trial. Cancer Prevention Research, 2021, 14, 753-762.	1.5	8
21	Ductal Lavage of Cancerous and Unaffected Breasts. Acta Cytologica, 2009, 53, 410-415.	1.3	7
22	Thorough in silico and in vitro cDNA analysis of 21 putativeBRCA1andBRCA2splice variants and a complex tandem duplication inBRCA2allowing the identification of activated cryptic splice donor sites inBRCA2exon 11. Human Mutation, 2018, 39, 515-526.	2.5	5
23	Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data. American Journal of Hematology/oncology, 2016, 12, 4-9.	0.0	4
24	Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations. Breast Journal, 2019, 25, 575-577.	1.0	3
25	Discrepancy Between Preference and Actual Adjuvant Therapy for Breast Cancer. Clinical Breast Cancer, 2010, 10, 398-403.	2.4	1
26	Family history matters. Cancer, 2016, 122, 2618-2620.	4.1	1
27	Quantitative Assessment of Learning Behaviors for Oncology Providers. Journal of Cancer Education, 2021, 36, 25-32.	1.3	1
28	Low-dose metronomic cyclophosphamide/methotrexate (LDCM) and aspirin for patients without pathologic complete response (pCR) after neoadjuvant treatment for stage II-III breast cancer Journal of Clinical Oncology, 2013, 31, 163-163.	1.6	1
29	Weekly vs Every-3-Week Carboplatin with Weekly Paclitaxel in Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Retrospective Analysis. Breast Cancer: Targets and Therapy, 2022, Volume 14, 63-70.	1.8	1
30	Placing negative multi-gene panel results into clinical context. Familial Cancer, 2017, 16, 595-595.	1.9	0
31	Establishing and Evaluating an ASCO Learning Cohort: a Longitudinal Project Assessing the Learning Needs and Behaviors of Oncology Professionals. Journal of Cancer Education, 2021, 36, 478-483.	1.3	0
32	Low-dose metronomic cyclophosphamide/methotrexate (LDCM) and aspirin for patients who fail to achieve pathologic complete response (pCR) after neoadjuvant treatment for stage II-III breast cancer Journal of Clinical Oncology, 2013, 31, e12000-e12000.	1.6	0
33	Change in mammographic density with metformin use: A companion study to NCIC study MA.32 Journal of Clinical Oncology, 2013, 31, TPS1608-TPS1608.	1.6	0